Literature DB >> 25035684

An unusual cause of thigh swelling: extramedullary myeloid tumor.

Memiş Hilmi Atay1, Engin Kelkitli2, Piltan Büyükkaya3, Kubilay Ekiz4, Levent Yıldız5, Mehmet Turgut3.   

Abstract

Entities:  

Keywords:  Acute leukemia; Acute myeloblastic leukemia; Granulocytes; Hemophagocytic lymphohistiocytosis

Year:  2014        PMID: 25035684      PMCID: PMC4102054          DOI: 10.4274/tjh.2013.0280

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.

TO THE EDITOR

Extramedullary myeloid tumor (EMMT) is a rare neoplasm of immature myeloid cells that arises at an extramedullary site [1]. The most common sites of EMMT are the bone, lymph nodes, skin, and soft tissue [2]. EMMT rarely infiltrates the lower extremities. A 47-year-old male patient was admitted to the orthopedics clinic because of swelling and pain in the right thigh for 1 month. His past medical history was unremarkable. Physical examination indicated a 10 cm-long solid soft tissue lesion in the anterior and lateral parts of the right thigh. Complete blood count results were as follows: white blood cell count of 15.1x109/L, hemoglobin level of 11.9 g/dL, and platelet count of 94x109/L. Magnetic resonance imaging (MRI) of the right thigh demonstrated a heterogeneous mass extending towards the distal part in the anterolateral section of the right femoral neck, completely involving the vastus lateralis and intermedius muscles (Figure 1). The patient underwent Tru-Cut biopsy of the right thigh. Pathology of the Tru-Cut biopsy showed large blastic cells infiltrating the soft tissue with hyperchromatic nuclei stained positively with CD117, CD34, and myeloperoxidase (Figure 2). After the Tru-Cut biopsy, blood count results were: white blood cells, 21.5x109/L, hemoglobin, 11.5 g/dL, and platelets, 74x109/L. Bone marrow aspiration showed 60% blasts, which were intensely positive for myeloperoxidase. Flow cytometry performed on the bone marrow revealed a blast population that expressed CD34, CD117, CD33, CD15, CD13, CD19, and HLA-DR. As a result of cytogenetic testing, a new complex karyotype related to chromosomes 8, 10, and 21 and trisomy 8 were detected. The patient was started on an acute myeloid leukemia (AML) induction chemotherapy regimen consisting of idarubicin (12 mg/m2, daily for 3 days) and cytosine arabinoside (ara-C; 200 mg/m2 continuous infusion for 7 days). After 4 weeks, the control bone marrow aspiration was completely normal. The lesion had also disappeared completely in the control MRI of the thigh. The patient was administered a high-maintenance dose of ara-C at 3 g/m2 for 6 days for consolidation. Treatment is ongoing.
Figure 1

A) Metaphysodiaphyseal paracortical heterogeneous enhancement of the proximal femur in the post-contrast T1-weighted coronal image. B) Paracortical minimal signal increase is seen in the proximal femoral metaphysodiaphyseal part in coronal T2-weighted fat-suppressed image.

Figure 2

A) Selected cytoplasm, large hyperchromatic nuclei, and tumor infiltration of cells showing marked pleomorphism (H&E, 40x). B) Diffuse strong membranous/cytoplasmic staining for CD34 in tumor cells and associated vascular structures (H&E, 40x). C) Membranous/cytoplasmic staining strong in some places and moderate in some places in tumor cells (CD117, 40x).

EMMTs are composed of myeloid blasts. They can easily be confused with lymphomas or soft tissue sarcomas [3,4]. EMMTs may accompany AML in 35% of patients at presentation, 38% of patients following diagnosis of AML, and 27% of patients without diagnosis of AML [5]. Cytogenetic abnormalities like translocation (8;22) or inversion 16 and 11q23 were reported in EMMT [6]. An optimal treatment approach does not exist due to the lack of randomized studies. Intensive chemotherapy regimens containing idarubicin plus ara-C are usually administered in the treatment of EMMT. According to the risk factors (age; molecular and cytogenetic study results), allogenic stem cell transplantation may also be considered. In the case of residual infiltration as shown by imaging, radiotherapy should be considered [7]. Consequently, EMMT might be taken into consideration in the differential diagnosis of venous thromboembolism and soft tissue malignancies in the case of swollen thighs.

CONFLICT OF INTEREST STATEMENT

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/ or affiliations relevant to the subject matter or materials included.
  7 in total

1.  [An unusual cause of hip pain: pelvic granulocytic sarcoma].

Authors:  Aksel Seyahi; Ata Can Atalar; Okan Soyhan; Mahmut Berkman
Journal:  Acta Orthop Traumatol Turc       Date:  2006       Impact factor: 1.511

2.  Myeloid sarcoma presenting in muscle-tissue of the lower limb: unusual origin of a compartment-syndrome.

Authors:  Susanne Scheipl; Andreas Leithner; Roman Radl; Christine Beham-Schmid; Gerhard Ranner; Werner Linkesch; Reinhard Windhager
Journal:  Am J Clin Oncol       Date:  2007-12       Impact factor: 2.339

3.  Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients.

Authors:  S A Pileri; S Ascani; M C Cox; C Campidelli; F Bacci; M Piccioli; P P Piccaluga; C Agostinelli; S Asioli; D Novero; M Bisceglia; M Ponzoni; A Gentile; P Rinaldi; V Franco; D Vincelli; A Pileri; R Gasbarra; B Falini; P L Zinzani; M Baccarani
Journal:  Leukemia       Date:  2006-12-14       Impact factor: 11.528

4.  Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.

Authors:  J C Byrd; R B Weiss; D C Arthur; D Lawrence; M R Baer; F Davey; E S Trikha; A J Carroll; R Tantravahi; M Qumsiyeh; S R Patil; J O Moore; R J Mayer; C A Schiffer; C D Bloomfield
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  How I treat extramedullary acute myeloid leukemia.

Authors:  Richard L Bakst; Martin S Tallman; Dan Douer; Joachim Yahalom
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

Review 6.  Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution.

Authors:  Massimo Breccia; Franco Mandelli; Maria C Petti; Mariella D'Andrea; Edoardo Pescarmona; Stefano A Pileri; Ida Carmosino; Eleonora Russo; Paolo De Fabritiis; Giuliana Alimena
Journal:  Leuk Res       Date:  2004-11       Impact factor: 3.156

7.  Granulocytic sarcoma presenting with malignant anasarca in a patient with secondary acute myeloid leukemia.

Authors:  Mohammad Y Khan; Khader K Hussein; Max G Walter; Muhammad K Hasan; William Kern; Mohamed A Kharfan-Dabaja
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.